drugset / Trial / NCT05159284

Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

NCT05159284

Phase 4 Unknown 54 enrolled Laboratorios Thea, Spain
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is assess the efficacy and safety of topical hydrocortisone (Softacort) for treatment of clinical signs and symptoms of dry eye disease when associated with moderate meibomian gland dysfunction.

Timeline

Start
2021-11-09
Primary completion
2024-12
Completion
2025-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified 1 unknown Topical

Indications